multiple inhalers on a white background Researchers explored the association between dry powder inhaler technique errors and exacerbations and health status in patients with COPD. Severe COPD ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

BALTIMORE, Aug. 16, 2023 /PRNewswire/ -- Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of global pharma major Lupin Limited (Lupin) today announced the launch of Tiotropium ...

COPD inhaled triple therapy (BDP/FF/G) improved symptoms, lung function, adherence, and QOL in patients previously treated with inhaled dual therapy.

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

Heidi M. Mansour, PhD, assistant professor in the University of Arizona College of Pharmacy, is working to develop advanced dry powder inhalers to treat and prevent pulmonary diseases. Dr. Mansour ...

Asthma inhalers are critical for delivering small amounts of medication to people's lungs to improve breathing and help prevent asthma attacks, but those tiny puffs add up to a large environmental ...

Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for ...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), today announced the launch of DUAKLIR® PRESSAIR® (aclidinium bromide and formoterol fumarate) for the ...

United Therapeutics Corp. announced that the FDA has approved the Tyvaso dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial ...

Chronic obstructive pulmonary disease (COPD) is a chronic lung condition characterized by loss of lung elasticity, which leads to dysfunctional gaseous exchange. COPD is the third leading cause of ...

The Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension ...